Fil: Thakur, Sidharath Dev. Department of Microbiology, College of Medicine; Estados Unidos.Fil: Araya, Pamela. Instituto de Salud Publica de Chile, Santiago; Chile.Fil: Borthagaray, Graciela. Faculdad de Quimica, Universidad de la Republica, Montevideo; Uruguay.Fil: Galarza, Patricia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Hernandez, Alina Llop. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Medicina Tropical; Argentina.Fil: Payares, Daisy. Instituto Nacional Higiene "Rafael Rangel", Caracas; Venezuela.Fil: Sanabria Cruz, Olga Marina. Instituto National de Salud, Bogota; Colombia.Fil: Carvallo, Maria Elena Trigoso. Centro Departmental de Vigilancia Information y Referencia, CDVIR La Paz; Bolivia.Fil: Corredor, Aura Helena. Vaccine and infectious Disease Organization-International Vaccine Center, University of Saskatchewan, Saskatchewan; Canada.Fil: Dillon, Jo-Anne R. Vaccine and infectious Disease Organization-International Vaccine Center, University of Saskatchewan, Saskatchewan; Canada.Seven countries in Latin America and the Caribbean report on (2010 and 2011) the susceptibility of 2235 isolates of Neisseria gonorrhoeae to 6 antibiotics. Thirteen isolates had ceftriaxone minimum inhibitory concentrations (MICs) of 0.125 to ≥ 0.25 mg/L. The percentage of resistant isolates to the following antibiotics was: azithromycin, 1.0% to 1.7%; ciprofloxacin, 42.1% to 36.2%; penicillin, 31% to 35%; tetracycline, 21.8% to 22.6%.